|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02666 UNI MEDICAL
Nominal 
5.030 +0.110 (+2.236%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 13,663,485 | 0.097% | 13,650,203 | 12,073,172 | 9,914,273 | 8,521,238 |
| Cost of Sales | (9,071,645) | -0.074% | (9,078,344) | (7,578,878) | (5,714,834) | (4,967,263) |
| Gross Profit | 4,591,840 | 0.437% | 4,571,859 | 4,494,294 | 4,199,439 | 3,553,975 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (322,980) | 68.132% | (192,099) | (307,139) | (318,235) | (247,446) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | (519) | -68.042% | (1,624) | (1,154) | (942) | -- | |
| Share of Results of Asso. & JCEs | 26,564 | 316.364% | 6,380 | 13,462 | 13,865 | 11,347 | |
| Profit / (Loss) before Taxation | 2,907,119 | 1.427% | 2,866,213 | 2,703,274 | 2,691,808 | 2,365,014 | |
| Taxation | (648,785) | -2.751% | (667,141) | (617,326) | (661,339) | (551,104) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (154,377) | 73.975% | (88,735) | (126,128) | (82,739) | (66,773) | |
| Others | (72,217) | -19.238% | (89,419) | (71,403) | (112,497) | (99,600) | |
| Profit / (Loss) Attributable to Shareholders | 2,031,740 | 0.535% | 2,020,918 | 1,888,417 | 1,835,233 | 1,647,537 | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (4,797) | -89.358% | (45,075) | (38,517) | (27,564) | (12,996) |
| Depreciation & Amortisation | 602,257 | 18.400% | 508,665 | 442,049 | 319,464 | 269,193 |
| Directors' Emoluments | 8,786 | -36.264% | 13,785 | 14,631 | 12,354 | 12,204 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 107.000 | 0.000% | 107.000 | 100.000 | 99.000 | 96.000 |
| DPS (cts) | 32.300 | -- | 31.740 | 29.788 | 29.264 | 26.154 |
| Dividend Payout Ratio (%) | 30.187% | -- | 29.664% | 29.788% | 29.559% | 27.243% |
| Cash flow per share ($) | 0.602 | -- | 2.640 | 1.074 | (0.753) | (0.566) |
| NBV per share ($) | 9.058 | -- | 8.248 | 7.351 | 6.888 | 6.275 |
| Remarks: | Real time quote last updated: 11/04/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 2,031,740 |
| %Change | 0.535% |
| EPS / (LPS) | RMB 1.070 |
| NBV Per Share (¥) | RMB 9.058 |